Novo Nordisk A/S (NYSE:NVO – Get Free Report)’s share price traded up 1.6% during mid-day trading on Monday . The stock traded as high as $38.59 and last traded at $38.57. 11,114,501 shares traded hands during trading, a decline of 56% from the average session volume of 25,406,488 shares. The stock had previously closed at $37.96.
Novo Nordisk A/S News Summary
Here are the key news stories impacting Novo Nordisk A/S this week:
- Positive Sentiment: Sanford C. Bernstein initiated coverage at “outperform” with a $175 price target — a very bullish stamp that can attract buyers and support shares despite recent weakness.
- Positive Sentiment: A new study found stopping GLP‑1 therapy raises risks of heart attack, stroke and death in Type 2 diabetes patients, reinforcing the clinical value and stickiness of GLP‑1 drugs like semaglutide (Wegovy/Ozempic), which supports long‑term demand. Healthy Returns: Stopping GLP-1s raises risk of heart attack, stroke and death, study says
- Positive Sentiment: Partnerships expanding access (e.g., Hims & Hers distribution of GLP‑1s) could broaden patient reach and support steady volume growth for Novo’s obesity/diabetes portfolio. Novo Nordisk (NVO) Partners With Hims & Hers, Here’s What You Need to Know
- Neutral Sentiment: Commentary pieces are debating whether the recent price decline makes NVO a value buy; that keeps investor attention high but creates mixed flows as value and momentum investors disagree. Is Novo Nordisk (NYSE:NVO) Starting To Look Interesting After A 52% One Year Slide?
- Negative Sentiment: New clinical data from a rival oral GLP‑1 (aleniglipron) showed weight‑loss results comparable to Wegovy, increasing competitive pressure in obesity — a direct threat to pricing and market share. Rival GLP-1 pill matches Wegovy weight loss data, adding to competitive pressure on Novo Nordisk
- Negative Sentiment: Reports say Novo Nordisk stands to lose key semaglutide patent protection in India soon, opening the door to low‑cost generics in a large, price‑sensitive market — a risk to long‑term sales and margin assumptions. Novo Nordisk Patent Loss In India Tests GLP 1 Valuation Story
- Negative Sentiment: The Portnoy Law Firm has opened an investigation into possible securities fraud involving Novo Nordisk, a headline that can prompt selling pressure and increase short‑term volatility. Novo Nordisk A/S Investigated by the Portnoy Law Firm
Analyst Ratings Changes
A number of analysts have weighed in on NVO shares. BMO Capital Markets restated a “market perform” rating on shares of Novo Nordisk A/S in a research note on Thursday, February 5th. HSBC reaffirmed a “hold” rating and set a $54.00 price objective on shares of Novo Nordisk A/S in a research report on Wednesday, December 10th. Zacks Research upgraded Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a report on Tuesday, March 10th. Sanford C. Bernstein initiated coverage on Novo Nordisk A/S in a research report on Wednesday. They set an “outperform” rating and a $175.00 target price on the stock. Finally, TD Cowen cut Novo Nordisk A/S from a “buy” rating to a “hold” rating and set a $42.00 target price for the company. in a research note on Tuesday, March 10th. Four equities research analysts have rated the stock with a Buy rating and nineteen have given a Hold rating to the company. Based on data from MarketBeat.com, Novo Nordisk A/S currently has a consensus rating of “Hold” and an average price target of $65.56.
Novo Nordisk A/S Price Performance
The stock has a market capitalization of $167.33 billion, a price-to-earnings ratio of 10.80 and a beta of 0.74. The company has a current ratio of 0.80, a quick ratio of 0.57 and a debt-to-equity ratio of 0.61. The company’s 50 day moving average is $49.45 and its 200 day moving average is $51.48.
Novo Nordisk A/S (NYSE:NVO – Get Free Report) last released its quarterly earnings data on Tuesday, February 3rd. The company reported $1.01 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.90 by $0.11. Novo Nordisk A/S had a net margin of 33.03% and a return on equity of 68.91%. The company had revenue of $12.43 billion during the quarter, compared to the consensus estimate of $11.97 billion. Research analysts anticipate that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.
Novo Nordisk A/S Dividend Announcement
The company also recently declared a dividend, which will be paid on Wednesday, April 8th. Investors of record on Monday, March 30th will be paid a dividend of $1.2751 per share. This represents a yield of 541.0%. The ex-dividend date is Monday, March 30th. Novo Nordisk A/S’s dividend payout ratio (DPR) is currently 52.74%.
Institutional Investors Weigh In On Novo Nordisk A/S
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Franklin Resources Inc. boosted its stake in Novo Nordisk A/S by 4,190.8% during the 3rd quarter. Franklin Resources Inc. now owns 13,984,789 shares of the company’s stock worth $776,016,000 after purchasing an additional 13,658,867 shares during the period. Capital International Investors increased its stake in Novo Nordisk A/S by 52.4% in the third quarter. Capital International Investors now owns 17,713,424 shares of the company’s stock valued at $982,969,000 after purchasing an additional 6,092,192 shares during the period. Boston Partners acquired a new position in Novo Nordisk A/S in the third quarter valued at $310,199,000. Price T Rowe Associates Inc. MD raised its holdings in shares of Novo Nordisk A/S by 99.7% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 9,688,262 shares of the company’s stock valued at $492,940,000 after buying an additional 4,836,285 shares during the last quarter. Finally, Voloridge Investment Management LLC boosted its stake in shares of Novo Nordisk A/S by 851.6% during the fourth quarter. Voloridge Investment Management LLC now owns 4,807,279 shares of the company’s stock worth $244,594,000 after buying an additional 4,302,126 shares during the period. Hedge funds and other institutional investors own 11.54% of the company’s stock.
About Novo Nordisk A/S
Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.
The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.
See Also
Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.
